A federal appeals court has upheld a previous ruling, invaliding patents for Acorda Therapeutics' multiple sclerosis drug Ampyra and opening the door for generic competition that could threaten the biotech's livelihood.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,